Europe Multiple Sclerosis Therapeutics Market

Market Introduction

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years.  It is a potentially debilitating disease, causing disruption in communication and coordination functions of the body.

Europe Multiple Sclerosis Therapeutics Strategic Insights

Strategic insights for the Europe Multiple Sclerosis Therapeutics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Multiple Sclerosis Therapeutics Report Scope

Europe Multiple Sclerosis Therapeutics Regional Insights

The geographic scope of the Europe Multiple Sclerosis Therapeutics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Europe multiple sclerosis therapeutics market is expected to reach US$ 13,281.11 million by 2027 from US$ 8,423.83 million in 2019; it is estimated to grow at a CAGR of 6.0% from 2020 to 2027. The growth of the market is attributed to a few key driving factors such as increasing awareness about multiple sclerosis amongst population, and development and launch of innovative products. However, the high cost of the multiple sclerosis treatment hinders the market growth.

In recent years, various measures and efforts have been taken to create awareness and educate people regarding neurological diseases, which are facilitating patients to access suitable medications and treatments for such conditions. The Multiple Sclerosis Foundation and affiliated groups have initiated National MS Education and Awareness Month, which is observed in March since 2003 to increase awareness about the disease. The goal of this program is to promote an understanding of multiple sclerosis disease and help the patients in making educated decisions regarding its treatment. Also, the National MS Society created and launched the “MS Kills Connection > < Connection Kills MS” campaign to connect people suffering from MS, people who treat MS patients, and people who run activities to create a world free of MS. Similarly, several players operating in the multiple sclerosis therapeutics market are developing and launching new products. The strategy of geographic and manufacturing capacity expansion, along with the product launches, helps companies cater to a broad customer base. Such developments and launches of new products are emerging as a key trend in the Europe multiple sclerosis therapeutics market.

Europe is recording the growing number of COVID-19 cases. Due to the second wave of COVID-19 outbreak, many countries' governments are working toward boosting up their cell therapies, gene therapies, and regenerative medicines produced by various companies.  Increasing COVID-19 cases affect the diagnosis and treatment of diseases due to the diversification of the medical workforce and decision to focus on treating the critically ill patients. Due to the current pandemic, many universities and research institutes stopped clinical trials, as scientists are shifting their focus on controlling the COVID-19 outbreak and are working hard to better study the virus. Thus, the growing focus on COVID-19 outbreak is hindering on the market growth.

Key Market Segments

The Europe multiple sclerosis therapeutics market, by drug class, is bifurcated into immunosuppressant and immunomodulators. The immunomodulators segment held a larger share of the market in 2019, whereas the immunosuppressants segment is anticipated to register a higher CAGR in the market during the forecast period.

The Europe multiple sclerosis therapeutics market, by route of administration, is bifurcated into injectable and oral. The injectable segment held a larger share of the market in 2019, and the same segment is anticipated to register a higher CAGR in the market during the forecast period.

Based on distribution channel, the Europe multiple sclerosis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held the largest share of the market in 2019. However, the e-commerce segment is estimated to register the highest CAGR in the market during the forecast period.

Major Sources and Companies Listed

Some of the primary and secondary sources associated with this report on the Europe multiple sclerosis therapeutics market are the European Centre for Disease Prevention and Control (ECDC), European Academy of Neurology (EAN) and European Medicines Agency (EMA).

Reasons to buy the report

• Determine prospective investment areas based on a detailed trend analysis of Europe multiple sclerosis therapeutics market over the next years.
• Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
• Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
• Identify the major channels driving the Europe multiple sclerosis therapeutics market, providing a clear picture of future opportunities that will help Analyze, resulting in revenue expansion.
• Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Europe multiple sclerosis therapeutics market.

EUROPE MULTIPLE SCLEROSIS THERAPEUTICS MARKET SEGMENTATION

By Drug Class

• Immunosuppressant
• Immunomodulators

By Route of Administration

• Injectable
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

By Country

• UK
• Germany
• France
• Italy
• Spain
• Rest of Europe

Company Profiles

• Merck & Co., Inc.
• Novartis AG
• Bayer AG
• Sanofi
• Bristol-Myers Squibb Company
• Horizon Therapeutics plc
• TEVA PHARMACEUTICAL INDUSTRIES LTD
• Takeda Pharmaceutical Company Limited
• F. HOFFMANN-LA ROCHE LTD
• Biogen